
TraceLink gases its traceability tank with a $51.5-million investment
Goldman Sachs jumps in, takes a board seat
TraceLink, the North Reading, MA, IT vendor that has carved out a leadership position in the software necessary for life sciences companies to meet the requirements of the
The company claims over 450 clients currently, which break down (according to a recent quarterly statement) to 27% pharma manufacturers and their CMOs, 10% wholesale distributors, and the remainder, dispensing companies such as pharmacy chains and health systems.
Jason Kreuziger from Goldman Sachs and Amish Jani of FirstMark Capital (the original funder of TraceLink) have joined its Board of Directors.
TraceLink continues to stress its foundation as a completely cloud-based (on Amazon Web Services), multitenant architecture as the best approach to meeting DSCSA compliance. “Unlike the common approach that most companies take to rent data center space from Amazon and stand up a hosted environment, TraceLink has taken advantage of AWS as a platform as a service (PaaS) by engineering our applications, business logic, workflows, exception handling, user management and network architecture from scratch within the AWS multitenant environment,” says a company spokesperson.
But the
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.





